| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27N3O4 |
| Molecular Weight | 409.4782 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(CN2N=C(CCCC3=CC=C(OC(C)(C)C(O)=O)C=C3)NC2=O)C=C1
InChI
InChIKey=PNHFDVSKDSLUFH-UHFFFAOYSA-N
InChI=1S/C23H27N3O4/c1-16-7-9-18(10-8-16)15-26-22(29)24-20(25-26)6-4-5-17-11-13-19(14-12-17)30-23(2,3)21(27)28/h7-14H,4-6,15H2,1-3H3,(H,27,28)(H,24,25,29)
| Molecular Formula | C23H27N3O4 |
| Molecular Weight | 409.4782 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
LY-518674 is a highly potent and selective proliferator-activated receptor (PPAR)-alpha agonist. LY-518674 produced a much greater increase in serum high-density lipoprotein-cholesterol (HDL-c) than the known fibrate drugs. The increase in HDL-c was associated with de novo synthesis of apolipoprotein A-1. It was being developed for the treatment of dyslipidemias with atherogenic potential.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
